BBP - BioShares Biotechnology Products ETF
| Assets | $29.08M |
| NAV | $52.88 |
| Expense Ratio | 0.79% |
| PE Ratio | n/a |
| Beta (5Y) | 1.05 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | Dec 20, 2017 |
| 1-Year Return | - |
| Trading Day | April 19 |
| Last Price | $52.04 |
| Previous Close | $52.88 |
| Change ($) | -0.84 |
| Change (%) | -1.58% |
| Day's Open | 52.85 |
| Day's Range | 51.99 - 52.16 |
| Day's Volume | 1,009 |
| 52-Week Range | 41.99 - 61.39 |
Fund Description
The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration (FDA) for marketing.
| Asset Class Portfolio-Multi Asset | Sector Biotech |
| Region North America | Inception Date Dec 17, 2014 |
| Exchange NYSEARCA | Ticker Symbol BBP |
| Index Tracked BioShares Biotechnology Products Index | |
Top 10 Holdings
28.82% of assets| Name | Symbol | Weight |
|---|---|---|
| Agios Pharmaceuticals | AGIO | 3.38% |
| Ligand Pharmaceuticals | LGND | 3.34% |
| United Therapeutics | UTHR | 3.06% |
| BeiGene | BGNE | 3.01% |
| Radius Health | RDUS | 2.95% |
| Vanda Pharmaceuticals | VNDA | 2.78% |
| Intra-Cellular Therapies | ITCI | 2.72% |
| Omeros | OMER | 2.55% |
| Enanta Pharmaceuticals | ENTA | 2.53% |
| Theravance Biopharma | TBPH | 2.50% |
As most corners of the market rallied on the slew of positive news, a few sectors scaled new highs. We have highlighted five ETFs from different sectors that hit all-time highs in the recent trading ses...
The S&P 500 posted its best third-quarter gains since 2010 with an advancement of 8.5%. The gains could continue as the October-December period is normally gainful for the market.
After a superb August, September turned gloomy for Wall Street.
The combination of lofty valuation, lack of additional fiscal stimulus package, election uncertainty and rising U.S.-China tensions weighed on investors' sentiment.
After a superb August, September looks gloomy for Wall Street. Still,
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.
While the rest of the biotechnology sector remained depressed along with the broader markets, related exchange traded funds found strength from an unexpected surge in ACADIA Pharmaceuticals (NasdaqGS: A...
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
